T1	Participants 242 277	patients with head-and-neck cancer.
T2	Participants 300 551	Fifty patients were randomized to receive conventional radiotherapy (RT) (2-Gy fractions, 5 days weekly, to a total of 60-74 Gy, depending on the tumor localization and TNM classification) and carboplatin (90 mg/m(2) infusion once per week before RT).
T3	Participants 966 990	amifostine-treated group
T4	Participants 1062 1075	control group
T5	Participants 1711 1743	patients with Grade 2 xerostomia
T6	Participants 2101 2135	patients with head-and-neck cancer
